Retired from engineering/management since 1997. Largely biotech, but some other stocks and real estate investor for over 25 years. Enjoy skiing, sailing, sports. I enjoy the role of Devil's Advocate, so some of what I say may be to provoke discussion, and may not reflect my actual opinion. I'm currently undergoing treatment for Acute Lymphoblastic Leukemia. I had planed to be skiing now, but sometimes life gets in the way of your plans. While I'm confident of achieving remission, I intend to be very critical of the FDA for the way drug testing is done. I'm strongly in favor of streamlining the clinical trial process, especially when related to drugs for potentially terminal diseases. I am scheduled for stem cell transplantation late this month (4/15).
I added stock and bond analysis to my IT consulting business at the request of a small cap investment specialist in 2002. For my own account I invest mainly in technology and biotechnology stocks, but occasionally I invest in industrial, retail and other stocks. My technology and investment web site is openicon.com. I still enjoy IT consulting and always have some sort of R&D project going on.
I have been investing in the stock market as a personal investor for approximately ten years now. I began my training in an accelerated pre-med program, and have continued both my interest and research in related topics. I only invest in companies after very lengthy deliberation, although am apt to leave the market entirely for periods of time. I have almost exclusively traded in the biotech sector.
My name is Tarun Chandra, and I've been an Analyst on both Buyside and Sellside. In addition, I've worked in Corporate Strategy and Finance roles for technology services companies. For many years I've been building quantitative models to create risk-adjusted, return-driven products for individual investors. Prudent Biotech portfolio is a quantitative-driven systematic investing product. More can be learnt about our Biotechnology portfolio at the website PrudentBiotech.com. You may also visit our website GraycellAdvisors.com for a view of our approach and all products.
Assumes multiple responsibilities in a leading global fintech firm, with current role developing quantitative models and investment strategies with a wide spectrum of financial data, in particular the proprietary index business by collaborating with index providers and fund sponsors to build smart-beta indices and prototypes. Holds a Master on Molecular Biology and Biochemistry from Fudan University Medical School, MBA from Case Western Reserve University Business School and is a Chartered Financial Analyst (CFA) member of New York Chapter (NYSSA).
Renaissance Capital is an IPO investment advisory firm providing pre-IPO institutional research and management of IPO-focused funds including the Renaissance IPO ETF (NYSE ticker: IPO), the Renaissance International IPO ETF (NYSE ticker: IPOS) and the Global IPO Mutual Fund (ticker: IPOSX). Through Renaissance Capital’s pre-IPO research service, investors get a hard-nosed, independent opinion, in-depth fundamental analysis and customizable financial models on all IPOs. The Firm's clients also gain access to the premier IPO knowledge base with deal calendars, market commentary, fundamental data on over 5,000 past IPOs and more.
Joe Kinahan (JJ), Chief Strategist for TD Ameritrade, began his career as a Chicago Board Options Exchange (CBOE) market maker in 1985, trading primarily in the S&P 100 (OEX) and S&P 500 (SPX) pits. While spending his time there primarily as an independent market maker, he also worked for ING Bank, Blue Capital and was Managing Director of Option Trading for Van Der Moolen, USA.
In 2006, Kinahan joined the thinkorswim Group, which was eventually acquired by TD Ameritrade. After leading the Educational Events Team, serving to implement the instructional path for thousands of investors throughout the United States, in 2009 he became the Managing Director of Active Trader Services.
Kinahan, a 26-year trading veteran, is a frequent CNBC guest, Forbes contributor and is often quoted in the Wall Street Journal, Financial Times and Reuters News, along with many other respected media outlets. He is also a member of the CBOE Arbitration Committee, OIC Roundtable and Board of Directors member at NYSE ARCA Equities and Options. His licenses include the 3, 4, 7, 24 and 66.
For the latest market observations and information follow JJ on Facebook or on Twitter, @TDAJJKinahan.
- Founder and developer of a software system designed to detect earnings management in companies.
- Freelance analysis
- Former analyst at Mitsubishi UFG.
- Education: Diplom Volkswirt in Economics - Johann Wolfgang Goethe University Frankfurt
Editor for The Biotech Forum, the #2 subscribed to Marketplace investment service offered through SeekingAlpha. Top 5% ranked analyst (TipRanks) 2013 through first half of 2015. Daily contributor for Real Money Pro. Hedge fund manager from 2008 to 2011. Previously technology executive at Fortune 100 firm for a decade.
Please go to biotechforumsa.com for more on the Biotech Forum service available through SeekingAlpha. For Free Investment Reports on a variety of topics go to bretjenseninvests.com
10 years investing in $10 or less stocks. My portfolio has grown from an initial $4K investment to well over a million in that period of time. I specialize in identifying under-the-radar, unloved stocks with great upside.
Wall Street Breakfast, Seeking Alpha's flagship daily business news summary, is a one-page summary that gives you a rapid overview of the day's key financial news. It's designed for easy readability on the site or by email (including on mobile devices), and is published before 7:00 AM ET every market day.
Wall Street Breakfast readership of over 900,000 includes many from the investment-banking and fund-management industries.
Sign up here to receive the Wall Street Breakfast in your inbox every business day: http://seekingalpha.com/account/email_preferences
Shane Skinner has invested in biotech companies for almost 20 years and placed over $2.6 million in biotech stock trades in 2013. He has held various financial leadership positions over the past 17 years throughout the United States and Europe including Chief Financial Officer. Shane graduated from Pepperdine University with an MBA, York College with a bachelor's degree in accounting, and is a licensed CPA. He was a collegiate soccer and rugby player and still plays in recreational leagues in Seattle. He has a wife, son, and one on the way!
Seeking Alpha's transcripts team is responsible for the development of all of our transcript-related projects. We currently publish thousands of quarterly earnings calls per quarter on our site and are continuing to grow and expand our coverage.
The purpose of this profile is to allow us to share with our readers new transcript-related developments.
SA Transcripts Team
Senior Portfolio Manager and individual investor who started in high school and has been at it ever since. I have an MBA and have earned the right to use the Chartered Financial Analyst designation. I have worked in the business for over 15 years. My specialties include fixed income closed-end funds for generating income during retirement, micro and small-cap value investing, and macro analysis.
BB Research, a group of capital market analysts, provides unique insights on the stocks it covers, mainly in the mid and small cap area. The group primarily focuses on news driven opportunities and aims at maximizing profits of the readers.
I joined Seeking Alpha in February 2014 as editor of the biotech vertical. In addition to onboarding new contributors, my job is to make sure Seeking Alpha provides high-quality and comprehensive coverage of the biotechnology and health care sectors. I am always looking for new ideas, so please reach out if you're interested.
My formal education ended with a Ph.D. in Biochemistry, minor in Organic Chemistry. After roughly two decades in academic research, my real-world education has continued at two biotech-related companies.
Michael Hopkins is a veteran journalist and editor, having spent 16 years in print and online media. His work includes 13 years as a managing and senior editor for various online news services operated by MediaBiz, including SkyREPORT, a top satellite industry news service.
In addition to MediaBiz, Michael has contributed articles to Light Reading, Satellite Business News and the SPECS newsletter from CableLabs, among other publications. In addition, he worked as a public relations professional with VisiTech PR, a firm focused on supporting technology clients in the United States and overseas. Michael also worked as a reporter for The Montrose Daily Press in Western Colorado.
Michael graduated from the University of Northern Colorado in 1992. He presently resides in Morrison, Colo., west of Denver.
Cory Renauer is a long-term dividend-growth investor. He is always on the lookout for well managed companies with predictable earnings growth, significant economic advantages over their competitors, and a commitment to increasing shareholder value.
I am an analyst and 2017 Level III Candidate in the CFA Program that has gained experience in the investment industry through positions as a proprietary trader and a portfolio management administrator. I began contributing to Seeking Alpha as a way to share my thoughts on the biopharmaceutical industry. I discussed ways to minimize risk in biopharmaceutical investing through conservative pipeline valuation and balance sheet analysis to identify companies presenting a compelling valuation to potential investors. I also touched on ways to apply knowledge of the markets to improve personal finance. My pieces included either stock-specific analysis or general biopharmaceutical investing discussion through my Biotech Weekly blog. My research appeared on the websites of CNBC, Seeking Alpha, Reuters, Google Finance, Morningstar, NASDAQ, and MarketWatch.
Note: Articles and comments are my own opinions, are not related to the opinions of my employer, and should not be considered investment advice. Make sure to do your own due diligence before making an investment decision. Thanks!
I'm a business graduate with an interest in discovering and writing about healthy investments, which are primarily focused on the healthcare sector.
The stock exchange is a fascination for me and I love to write about any aspect of it.
Work in healthcare but trading securities is my passion. Business degree from Pepperdine University. Looking to retire in the next couple of years so that I can enjoy the finer things in life on a full time basis. :-)
Biomed Group is an independent research group, with a goal of providing investors with real-time information and exclusive specialised research on biotechnology stocks, so that they can make informed investment decisions.
I am a market enthusiast and part-time trader. I started writing for Seeking Alpha in 2011, and it has been a tremendous opportunity and learning experience. I have been interested in the markets since elementary school, and hope to pursue a career in the investment management industry. I have been active in the markets for several years, and am primarily focused on long/short equities.
I hold a Bachelor of Science Degree from Lehigh University, where I double majored in Finance and Accounting, with a minor in History. My major track focused on Investments and Financial Analysis. While at Lehigh, I was the Head Portfolio Manager of the Investment Management Group, a student group that manages three portfolios, one long/short and two long only. I have had two internships, one a summer internship at a large bank, and another helping to manage the Lehigh University Endowment for nearly a year.
Disclaimer: Bill reminds investors to always due their own due diligence on any investment, and to consult their own financial adviser or representative when necessary. Any material provided is intended as general information only, and should not be considered or relied upon as a formal investment recommendation.